OMER Jan 2025 2.000 put
| Previous Close | 0.5000 |
| Open | 0.5000 |
| Bid | 0.2000 |
| Ask | 0.7500 |
| Strike | 2.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 0.5000 - 0.5000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 60 |
Business WireOmeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
SEATTLE, June 01, 2023--Omeros Corporation (Nasdaq: OMER) today announced that data from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder, will be shared at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany. Identified as one of the top five late-breaking submiss
Business WireOmeros Corporation Reports First Quarter 2023 Financial Results
SEATTLE, May 09, 2023--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2023, which include:
Business WireOmeros Corporation to Announce First Quarter Financial Results on May 9, 2023
SEATTLE, May 04, 2023--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Business WireOmeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
SEATTLE, April 25, 2023--Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder. Statistically significant and clinically meaningful improvements were observed in all measured markers of hemolysis, including hemoglobin (Hgb)
Business WireOmeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
SEATTLE, April 10, 2023--Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD). The grant is expected to provide $6.69 million over three years and is intended to support both preclinical cocaine interaction studie
ZacksAvis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day
Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day.
Zacks3 Medical Stocks Creating Wealth Despite Macro Challenges
Here we discuss three stocks - LNTH, OMER and HYPR - that have been creating wealth for their investors in 2023 even though several competitors faltered amid macro challenges. Will the trend continue?
Insider MonkeyOmeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript March 13, 2023 Operator: Good afternoon. And welcome to today’s earnings call from Omeros Corporation. At this time, all participants are in a listen-only mode. After the company’s remarks, we will conduct a question-and-answer session. Please be advised that this call is being recorded at the company’s […]
Business WireOmeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
SEATTLE, March 13, 2023--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022, wh
Business WireOmeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
SEATTLE, March 10, 2023--Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.
Business WireOmeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
SEATTLE, March 07, 2023--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Motley FoolWhy Omeros Stock Bolted Higher This Week
Shares of Omeros (NASDAQ: OMER) rose by a stately 69.9% through the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. Shares of the commercial-stage biopharmaceutical company jumped this week in response to a $200 million milestone payment from Rayner Surgical. The payment stems from Rayner's 2021 asset purchase agreement of Omidria, which is an ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement.
Motley FoolWhy Omeros Corporation Stock Is Skyrocketing Today
Shares of Omeros Corporation (NASDAQ: OMER) skyrocketed 40.5% higher as of 11:12 a.m. ET on Monday. The huge gain came after the company announced that Rayner Surgical paid a $200 million milestone payment. This payment is related to Omeros' sale of its ophthalmology product Omidria to Rayner in December 2021.
Business WireOmeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
SEATTLE, February 06, 2023--Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. ("Rayner") has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021 (the "Agreement"), pursuant to which Omeros sold its ophthalmology product OMIDRIA® to Rayner in December of 2021.
Business WireOmeros Corporation Reports Third Quarter 2022 Financial Results
SEATTLE, November 09, 2022--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2022, which include:
Business WireOmeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
SEATTLE, November 08, 2022--Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has reached a decision on the company’s formal dispute resolution request appealing the issuance by FDA’s Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) and the Division of Nonmalignant Hematology (the review division) of a complete response letter (CRL) concerning the biologics license application (BLA) for narsop
Business WireOmeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
SEATTLE, November 04, 2022--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Business WireOmeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
SEATTLE, November 03, 2022--Omeros Corporation (Nasdaq: OMER) today announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting, which will be held from December 10-13, 2022 in New Orleans. The following abstracts were published today and are now available on the ASH website at www.hematology.org:
Business WireOmeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
SEATTLE, October 03, 2022--Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP ("DRI"), a wholly owned subsidiary of DRI Healthcare Trust, an interest in certain royalty payments based on net sales of OMIDRIA (the "Purchased Receivables"). The royalties payable to DRI comprise a portion of the royalties projected to be paid under the terms of the Asset Purchase Agreement (the "Asset Purchase Agreement"), among Omeros, Rayner Surgical Inc. ("Ra
BenzingaOmeros COVID-19 Treatment Reduced Mortality Risk, But Biased Data Rendered Analysis Meaningless
Omeros Corp (NASDAQ: OMER) reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. The company said that in approximately half of the patients died in the narsoplimab group, and narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Omeros adds that despite narso
Business WireOmeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
SEATTLE, September 15, 2022--Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk (hazard ratio [HR]=0.81, with probability [HR <1] equal to 0.77). Narsoplimab showed the largest reduction in mortality risk to date acros
Business WireI-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
SAN FRANCISCO & SEATTLE, September 15, 2022--Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed in the narsoplimab arm of the I-SPY COVID Trial. The analysis in the randomized patient population, including those who declined treatment after randomization, shows that the addition of narsoplimab to treatment of
Business WireOmeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
SEATTLE, August 17, 2022--Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by the FDA review division to issue a complete response letter for the biologics license application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-
Business WireOmeros Corporation Reports Second Quarter 2022 Financial Results
SEATTLE, August 09, 2022--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2022, which include: